Bio-Rad Laboratories (BIO) Expected to Release Earnings on Wednesday

Bio-Rad Laboratories (NYSE:BIO) is projected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Bio-Rad Laboratories to announce earnings of $2.23 per share and revenue of $649.94 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.75 by $0.87. The business had revenue of $651.00 million for the quarter, compared to the consensus estimate of $623.99 million. Bio-Rad Laboratories’s quarterly revenue was down .1% on a year-over-year basis. During the same period in the prior year, the company earned $2.61 EPS. On average, analysts expect Bio-Rad Laboratories to post $9.28 EPS for the current fiscal year and $8.89 EPS for the next fiscal year.

Bio-Rad Laboratories Stock Up 2.2%

BIO opened at $380.58 on Wednesday. The firm has a market cap of $10.18 billion, a price-to-earnings ratio of 46.13 and a beta of 1.07. Bio-Rad Laboratories has a fifty-two week low of $236.73 and a fifty-two week high of $396.23. The company’s 50-day moving average price is $374.06 and its 200 day moving average price is $313.22.

Wall Street Analysts Forecast Growth

BIO has been the subject of several recent research reports. Citigroup upped their target price on Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded Bio-Rad Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Royal Bank Of Canada boosted their price objective on Bio-Rad Laboratories from $320.00 to $370.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, Wells Fargo & Company increased their target price on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $343.33.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures and markets products and systems used in life science research and clinical diagnostics. Its life science portfolio includes laboratory instruments, reagents, software and consumables used in areas such as genomics, proteomics, cell biology, biopharmaceutical development and quality control.

The company’s clinical diagnostics business provides systems, reagents and software for blood typing, infectious disease testing, diabetes monitoring, quality control and other diagnostic applications.